Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110δ subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors

Leukemia Research

Volumn 37, Issue 6, 2013, Pages 697-704

  Xing, Yan ^a   Hogge, Donna E ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

AML; Drug combination; MEK1 MEK2; P110 ; PCN5603; Small molecule inhibitor; Targeted therapy; U0126

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTILEUKEMIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN EXTRACELLULAR ACTIVATED PROTEIN KINASE; P110 DELTA PROTEIN; PCN 5603; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SERINE; TYROSINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD CELL; CANCER STEM CELL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELLS, CULTURED; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MIDDLE AGED; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; YOUNG ADULT;

EID: 84877015531     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.03.003     Document Type: Article

References (48)

1. Grandage V.L., Gale R.E., Linch D.C., Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005, 19:586-594.
2. Franke T.F. PI3K/Akt: getting it right matters. Oncogene 2008, 27:6473-6488.
3. Chantry D., Vojtek A., Kashishian A., Holtzman D.A., Wood C., Gray P.W., et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997, 272:19236-19241.
4. Guillermet-Guibert J., Bjorklof K., Salpekar A., Gonella C., Ramadani F., Bilancio A., et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA 2008, 105:8292-8297.
5. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
6. Kim S.Y., Kang J.J., Lee H.H., Kim B., Kim C.G., Park T.K., et al. Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816. Biochem Biophys Res Commun 2011, 410:224-228.
7. Xing Y., Gerhard B., Hogge D.E. Selective small molecule inhibitors of p110alpha and delta isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors. Exp Hematol 2012, 40:922-933.
8. Sujobert P., Bardet V., Cornillet-Lefebvre P., Hayflick J.S., Prie N., Verdier F., et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005, 106:1063-1066.
9. Daver N., Cortes J. Molecular targeted therapy in acute myeloid leukemia. Hematology 2012, 17(Suppl. 1):S59-S62.
10. Young A., Lyons J., Miller A.L., Phan V.T., Alarcon I.R., McCormick F. Ras signaling and therapies. Adv Cancer Res 2009, 102:1-17.
11. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001, 410:1111-1116.
12. Wellbrock C., Karasarides M., Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004, 5:875-885.
13. Lyons J.F., Wilhelm S., Hibner B., Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001, 8:219-225.
14. McCubrey J.A., Steelman L.S., Kempf C.R., Chappell W.H., Abrams S.L., Stivala F., et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 2011, 226:2762-2781.
15. Steelman L.S., Franklin R.A., Abrams S.L., Chappell W., Kempf C.R., Basecke J., et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011, 25:1080-1094.
16. James J.A., Smith M.A., Court E.L., Yip C., Ching Y., Willson C., et al. An investigation of the effects of the MEK inhibitor U0126 on apoptosis in acute leukemia. Hematol J 2003, 4:427-432.
17. Kerr A.H., James J.A., Smith M.A., Willson C., Court E.L., Smith J.G. An investigation of the MEK/ERK inhibitor U0126 in acute myeloid leukemia. Ann N Y Acad Sci 2003, 1010:86-89.
18. Martelli A.M., Nyakern M., Tabellini G., Bortul R., Tazzari P.L., Evangelisti C., et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006, 20:911-928.
19. She Q.B., Halilovic E., Ye Q., Zhen W., Shirasawa S., Sasazuki T., et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010, 18:39-51.
20. Halilovic E., She Q.B., Ye Q., Pagliarini R., Sellers W.R., Solit D.B., et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 2010, 70:6804-6814.
21. Janku F., Lee J.J., Tsimberidou A.M., Hong D.S., Naing A., Falchook G.S., et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE 2011, 6:e22769.
22. Kubo K., Naoe T., Kiyoi H., Fukutani H., Kato Y., Oguri T., et al. Clonal analysis of multiple point mutations in the N-ras gene in patients with acute myeloid leukemia. Jpn J Cancer Res 1993, 84:379-387.
23. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7:295-308.
24. Bowen D.T., Frew M.E., Hills R., Gale R.E., Wheatley K., Groves M.J., et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 2005, 106:2113-2119.
25. Castellano E., Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2011, 2:261-274.
26. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
27. Muranyi A.L., Dedhar S., Hogge D.E. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells. Exp Hematol 2009, 37:450-460.
28. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 1989, 42:567-584.
29. Grimwade D., Hills R.K., Moorman A.V., Walker H., Chatters S., Goldstone A.H., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
30. Tsuchiya S., Yamabe M., Yamaguchi Y., Kobayashi Y., Konno T., Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980, 26:171-176.
31. Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998, 273:18623-18632.
32. Ailles L.E., Gerhard B., Hogge D.E. Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood 1997, 90:2555-2564.
33. Hogge D.E., Lansdorp P.M., Reid D., Gerhard B., Eaves C.J. Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor. Blood 1996, 88:3765-3773.
34. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
35. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18:189-218.
36. Gutiyama L.M., Coutinho D.F., Lipkin M.V., Zalcberg I.R. Myeloid neoplasias: what molecular analyses are telling us. ISRN Oncol 2012, 2012:321246.
37. Takahashi S. Inhibition of the MEK/MAPK signal transduction pathway strongly impairs the growth of Flt3-ITD cells. Am J Hematol 2006, 81:154-155.
38. Sebolt-Leopold J.S., English J.M. Mechanisms of drug inhibition of signalling molecules. Nature 2006, 441:457-462.
39. Yajima I., Kumasaka M.Y., Thang N.D., Goto Y., Takeda K., Yamanoshita O., et al. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012, 2012:354191.
40. Roberts P.J., Usary J., Darr D., Dillon P.M., Pfefferle A.D., Whittle M.C., et al. Combined PI3K/mTOR and MEK inhibition provides broad anti-tumor activity in faithful murine cancer models. Clin Cancer Res 2012, 18:5290-5303.
41. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356.
42. Kinkade C.W., Castillo-Martin M., Puzio-Kuter A., Yan J., Foster T.H., Gao H., et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008, 118:3051-3064.
43. Miller K.A., Yeager N., Baker K., Liao X.H., Refetoff S., Di Cristofano A. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 2009, 69:3689-3694.
44. Shelton J.G., Steelman L.S., Lee J.T., Knapp S.L., Blalock W.L., Moye P.W., et al. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene 2003, 22:2478-2492.
45. Rubnitz J.E., Gibson B., Smith F.O. Acute myeloid leukemia. Hematol Oncol Clin North Am 2010, 24:35-63.
46. Wang E.S., Yee K., Koh L.P., Hogge D., Enschede S., Carlson D.M., et al. Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leuk Lymphoma 2012, 53:1543-1551.
47. Stone R.M., DeAngelo D.J., Klimek V., Galinsky I., Estey E., Nimer S.D., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005, 105:54-60.
48. Chappell W.H., Steelman L.S., Long J.M., Kempf R.C., Abrams S.L., Franklin R.A., et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011, 2:135-164.